Vaccines comprising truncated HBC core protein plus saponin-based adjuvants

An adjuvant and saponin technology, applied in the field of vaccines containing truncated HBC core protein and saponin-based adjuvants, can solve problems such as weak immune responses

Inactive Publication Date: 2013-03-13
RAJN BIOTEKH GEZELLSHAFT FJUR NOJE BIOTEKHNOLOGISHE PROTSESSE & PROD MBKH
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In animal models (mice), DNA vaccines, especially DNA vaccines based on plasmid vectors encoding hepatitis B virus core antigen (HBcAg), can achieve significant CTL responses, but all current vaccines so far have only shown very limited responses in humans. Weak immune response and does not stimulate any effective CTL response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines comprising truncated HBC core protein plus saponin-based adjuvants
  • Vaccines comprising truncated HBC core protein plus saponin-based adjuvants
  • Vaccines comprising truncated HBC core protein plus saponin-based adjuvants

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0148] In the first series of experiments, the product description will be A commercially available saponin complex at -100 (ISCONOVA, Uppsala, Sweden) was used as adjuvant. Core plasmid DNA was used as a positive control, pure PBS, pure adjuvant in PBS, pure HBc in PBS 1-144+I And HBcl-183 in PBS served as a negative control. The composition of the present invention comprises PBS, HBc 1-144+I and -100. The amount of each component is shown in Table 1.

[0149] Plasmid pCI / HBV ayw Core basis A., Pudollek H.P., Reifenberg K., Chisari F.V., Schlicht H.J., Reimann J., Schirmbeck R. (1996): DNA Immunization Induces Antibodies and Cytotoxic T Cells to Hepatitis B Core Antigen in H-2b Mice Reaction", J.Immunol.156:3687-95 (the construct is called pCMV-1 / c there), its isolation was carried out according to Carried out according to the manufacturer's instructions.

[0150] For the formulation of the composition of the present invention, HBc 1-144+I First dilute to 4 tim...

Embodiment 2

[0156] In the following series of experiments, in the product description A commercially available saponin complex at -200 (ISCONOVA, Uppsala, Sweden) was used as adjuvant. Core plasmid DNA as positive control; pure PBS, pure adjuvant in PBS, pure HBC in PBS 1-144+I and pure HBc in PBS 1-183 as a negative control. The composition of the present invention comprises PBS, HBc 1-144+I , -200 and optionally HBsAg. The amount of each individual component is shown in Table 2.

[0157] For the formulation of the composition of the present invention, HBc 1-144+I And optionally the HBsAg is firstly diluted with PBS to 4 times the final product concentration, and incubated at 37° C. for 30 minutes with shaking. When using HBsAg, first, HBsAg and HBcAg 1-144+I Mix under sterile conditions and dilute likewise with PBS to 4 times the final product concentration. -200 (in the form of an aqueous dispersion supplied by the manufacturer) was then added and the final antigen concent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

Composition (A) comprises (i) one or more hepatitis B core antigens (HBcAg) containing amino acids 1 to x (x = 100-160),their fragments, variants of fragment variants; (ii) an adjuvant containing a saponin and / or saponin derivative; and (iii) optionally, one or more hepatitis B surface antigens (HBsAg), or their fragments, variants or variant fragments. - ACTIVITY : Virucide; Hepatotropic; Antiinflammatory. Mice were immunized with a composition containing 5 mu g AbISCO-200 (RTM for a saponin composition) and 10 mu g HBcAg1-144+1 in 0.1 ml phosphate-buffered saline. The number of CD8+> cells that expressed gamma -interferon was just over 100 per 105> such cells; compared with zero when the same antigen was administered without saponin. When the composition also contained 5 mu g HBsAg, the number of such cells was 170 / 105>. The composition also resulted in high levels of immunoglobulins G1 and G2b, indicating a Th1 / Th2 response. - MECHANISM OF ACTION : Vaccine.

Description

technical field [0001] The present invention relates to a composition, a method for producing the composition, a composition obtainable by the method, a pharmaceutical preparation, the composition or the pharmaceutical preparation in the treatment and / or prevention of hepatitis B virus (HBV) infection and HBV-mediated The use of the composition or the pharmaceutical preparation in the production of medicines for the treatment and / or prevention of HBV infection and HBV-mediated diseases, and the treatment and / or prevention of HBV infection and HBV-mediated diseases method. Background of the invention [0002] According to World Health Organization (WHO) estimates, more than 2 billion people are infected or have been infected with hepatitis B virus (HBV) today. Thus, HBV belongs to the most important human pathogens with enormous impact on human health. [0003] HBV infection can occur via blood, contaminated blood products, and through sexual intercourse, wherein the infect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/02A61K39/39A61P31/04
CPCA61K2039/55577A61K39/29C12N2730/10122C12N2770/24222C12N2770/24234C07K14/005A61K39/39A61K2039/53A61K2039/57C12N2730/10134A61K39/12A61P1/16A61P31/04A61P31/20A61P37/04C07K14/02
Inventor K·梅尔贝尔P·布基曼Z·亚诺维奇
Owner RAJN BIOTEKH GEZELLSHAFT FJUR NOJE BIOTEKHNOLOGISHE PROTSESSE & PROD MBKH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap